Changes in neurotransmitter-related functional connectivity along the Alzheimer's disease continuum

Running title: Connectivity in Alzheimer's disease

Riccardo Manca^{1,2}, Matteo De Marco¹, Hilkka Soininen³, Livia Ruffini⁴, Annalena Venneri^{1,2}

¹ Department of Life Sciences, Brunel University of London, London, UK

² Department of Medicine and Surgery, University of Parma, Parma, Italy

³ Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland

⁴ Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy

Corresponding author:

Professor Annalena Venneri

Department of Life Sciences, Brunel University of London, Kingston Lane, UB8 3PH, London,

UK

Email: annalena.venneri@brunel.ac.uk

Abstract

Alzheimer's disease (AD) may be associated with early dopamine (DA) dysfunction. However, its effects on neurofunctional alterations in the neurotransmission pathways remain elusive. In this study, PET atlases and functional MRI data for 86 older adults with mild cognitive impairment (AD-MCI), 58 with mild AD dementia and 76 cognitively unimpaired (CU) were combined to investigate connectivity alterations associated with the dopaminergic and cholinergic (ACh) systems. A cross-sectional design was used to compare neurotransmitter-related functional connectivity across groups and associations between functional connectivity and cognitive performance.

The findings show that the AD-dementia group showed a decline in mesocorticolimbic DArelated connectivity in the precuneus but heightened connectivity in the thalamus, whereas the AD-MCI group showed a decline in nigrostriatal connectivity in the left temporal areas. AChrelated connectivity decline was observed in both AD-MCI and AD-dementia primarily in the temporo-parietal areas. Episodic memory scores correlated positively with ACh- and DArelated connectivity in the temporo-parietal cortex and negatively with DA-related FC in the fronto-thalamic areas. This study shows that connectivity alterations in ACh and DA functional pathways parallel cognitive decline in AD and might be a clinically relevant marker in early AD.

Keywords: Alzheimer's disease; neurotransmitters; functional connectivity; PET; MRI.

Introduction

Although diagnostic criteria for Alzheimer's disease (AD) are based on established biological markers, the AT(N) [i.e. Amyloid Tau (Neurodegeneration)] system is flexible, and recognises the importance of other mechanisms that may contribute to AD aetiopathogenesis.¹ Many mechanisms still need to be fully clarified, and more research is needed to detect and characterise them in detail. In this respect, the vulnerability of the "isodendritic core", a set of interconnected brainstem nuclei in the reticular formation, has long been proposed as a major player in a range of neurodegenerative diseases, including AD.^{2,3} Many of these nuclei send projections to the medial temporal lobe, a territory that is significantly affected by AD. However, only recently increasing efforts have been made to establish the exact alterations that occur in the brainstem at the pre-symptomatic stages of AD. A recent neuropathological investigation identified accumulation of cytoskeletal pathology (due to hyperphosphorylated tau protein) across multiple brainstem nuclei at "Braak Stage 0", before any pathological changes are detected in the transentorhinal cortex.⁴ This finding suggests that, although neuronal damage in the basal forebrain and the subsequent dysfunction in acetylcholine (ACh) production have long been established in AD,⁵ they may not be the primary cause of altered neurotransmission in AD. Indeed, not all ACh-producing neurons (e.g., those in the brainstem) are heavily affected by AD pathology.6

The role of dopamine (DA) dysfunction in AD has been investigated in a mouse model expressing a mutated version of the human amyloid precursor protein: neuronal loss in the ventral tegmental area (VTA), but not in the substantia nigra (SN), anticipated alterations in hippocampal neuron function and memory performance.^{7,8} Additional findings have emerged from studies carried out on cognitively-unimpaired (CU) older adults and people with AD. De Marco & Venneri⁹ found that smaller VTA volume values were significantly associated with smaller hippocampal volumes and worse episodic memory performance, particularly in CU

older adults. Moreover, lower functional connectivity (FC) between VTA and left hippocampus was associated with hippocampal atrophy, while episodic memory performance was positively associated with FC between the VTA and mediofrontal areas. Serra et al.¹⁰ found that the FC of the VTA, but not of the locus coeruleus, was progressively less expressed along the AD continuum and was associated with neuropsychiatric symptoms. In detail, compared with CU, FC between the VTA and the right parietal cortex was weaker in people with mild cognitive impairment (MCI), while a more pronounced FC decline was observed in patients with dementia due to AD throughout all cortical regions of the posterior Default Mode Network (DMN).

Moreover, a significant alteration in the structural integrity of the VTA, but not of any other brainstem nuclei, was observed in CU older adults before progression to MCI, although no differential rate of longitudinal VTA signal decline was observed between older adults who progressed to MCI and those who remained unimpaired.¹¹

The few available MRI studies that have included participants with AD have important limitations. Volumetric estimates of small brainstem nuclei might be suboptimal, since MRI sequences that are more suitable for visualising small DA-containing brainstem nuclei, e.g., neuromelanin-sensitive MRI,¹² have not been consistently used. It is also not clear whether different subcortical/cortical regions that receive projections from the VTA may be equally affected in AD, and whether the mesocorticolimbic pathway may be more vulnerable to early disease processes than the nigrostriatal pathway, as suggested by a recent positron emission tomography (PET) study.¹³ Moreover, multimodal investigations that combine different neuroimaging modalities are lacking.

To overcome the above-mentioned limitations and to ascertain the potential involvement of DA in the neurofunctional processes underlying AD, the present study was designed to combine PET atlases that illustrate the distribution of neurotransmitter receptors and

transporters with functional MRI to: 1) investigate differences in DA-related FC across the clinical spectrum of AD (i.e., in three diagnostic groups of CU, MCI due to AD, i.e., AD-MCI, and dementia due to AD, i.e., AD-dementia); 2) test whether alterations in DA-related FC are associated with worse cognitive performance across groups. ACh-related FC maps were also analysed to investigate the cholinergic system as a second pathway of established relevance in AD.

Materials and methods

Participants

This study was a retrospective analysis of the dataset of the "Virtual Physiological Human: DementiA RESearch Enabled by IT" (VPH-DARE@IT) project. VPH-DARE@IT was a multicentre study funded by the EU (Framework Programme 7, FP7/2007-2013, Grant Agreement no. 601055) with the aim of providing a comprehensive modelling approach to improve the diagnosis and prognosis of dementia. Two-hundred-twenty participants were included in this study: 86 older adults with a clinical diagnosis of MCI due to AD (AD-MCI),¹⁴ 58 with dementia due to AD (AD-dementia)¹⁵ and 76 CU controls. The AD-MCI group included 28 amnestic single-domain, 36 amnestic multi-domain, 16 non-amnestic singledomain and six non-amnestic multi-domain cases. Participants were recruited between December 2013 and June 2017 across three sites: the Institute of Clinical Medicine in Kuopio (Finland), the memory clinic at the Royal Hallamshire Hospital in Sheffield (United Kingdom) and the San Camillo IRCCS Hospital Foundation in Venice (Italy). Patients were approached and invited to take part in this study in a clinical diagnostic setting and mostly recruited at time of first diagnosis. Eligible patients were provided with informational material about the study if they met inclusion criteria. CU older adults were recruited via leaflets and adverts in the local communities, among patients' carers and by word of mouth. Participants were selected from

the larger sample included in the VPH-DARE@IT project only if the necessary neuroimaging and cognitive data were available. Participants with missing data or with neuroimaging data that did not pass quality control were not considered for inclusion in this study.

All procedures were carried out in compliance with the Declaration of Helsinki and written informed consent was obtained from all participants. Ethical approval was obtained for each sub-cohort from the ethics committee of the Northern Savonia Hospital District (Ref No: 77/2013), the Yorkshire and Humber Regional Ethics Committee (Ref No: 12/YH/0474) and from the ethics committee of the Health Authority Venice and San Camillo IRCCS (Ref No: 2014.08).

The general inclusion and exclusion criteria for the VPH-DARE@IT project have been extensively reported in previous studies.¹⁶ Briefly, patients with potential non-neurodegenerative causes (e.g., cerebrovascular disease, psychiatric problems, abnormal levels of vitamin B12) of cognitive decline were excluded. Moreover, participants with evidence of medication/substance use known to influence dopaminergic neurotransmission, or with MRI evidence of abnormalities other than the effects of either ageing or neurodegeneration were also excluded. Information regarding ongoing acetylcholinesterase inhibitor (AChEI) treatment and positivity status for both amyloid beta (A β) and phosphorylated tau (p-tau), determined in clinical settings by means of any available biomarkers (i.e., cerebrospinal fluid, PET or blood examination), was also recorded.

Additional inclusion criteria for this study were: 1) availability of all demographic information; 2) availability of good-quality structural (T1-weighted) and functional (T2*-weighted) MRI scans; and 3) availability of at least one cognitive test score common to all three participant cohorts. Although there were no selection criteria about ethnicity and race, this culturally diverse sample included only participants of primarily White Caucasian ethnic background

 (only one AD-dementia patient and one CU control were of an Afro-Caribbean background and one MCI patient and one CU control were of an Indian background).

Cognitive assessment

For this study, a set of seven cognitive measures common to all cohorts was selected: the Logical Memory Test (immediate and delayed recall),¹⁷ the Letter Fluency Test (total score, based on language-dependent and clinically established phonological cues),¹⁸ the Similarities Test,¹⁷ the Stroop Test (time interference calculated on the 30-item version)¹⁹ and the Digit Span Test (forwards and backwards scores).¹⁷

To enable the integration and comparison of the different sub-cohorts, all raw cognitive test scores were transformed into z-scores using the means and standard deviations of each cohort's CU group. A composite score for global cognitive performance was created by averaging the z-scores. The composite score was calculated for 215 participants only, as five participants had only three or fewer cognitive measures.

MRI acquisition

MRI scans were acquired using a shared acquisition protocol across sites on a Philips Achieva 3T scanner in Kuopio and a Philips Ingenia 3T scanner in Sheffield and Venice. All data were collected using the same acquisition parameters that had been harmonised using the ADNI protocol (https://adni.loni.usc.edu/data-samples/adni-data/neuroimaging/mri/mri-scanner-protocols/). The scanning protocol included T1-weighted, T2-weighted, Fluid Attenuated Inversion Recovery, and T2*-weighted resting-state functional MRI scans.¹⁶ Structural images were reviewed by a senior neuroradiologist to ensure that the study criteria were met. Only T1-weighted and T2*-weighted images were used in this study. T1-weighted scans were acquired using a Magnetization Prepared Rapid Acquisition Gradient Echo technique (voxel

dimensions = $0.94 \times 0.94 \times 1.00 \text{ mm}^3$, repetition time = 8.2 s, echo time = 3.8 ms, inversion time = 1 s, flip angle = 8°). T2*-weighted scans were acquired at rest while participants were laying as still as possible with eyes closed (35 axial slices, reconstructed in-plane voxel dimensions = $1.8 \times 1.8 \text{ mm}^2$, slice thickness = 4.0 mm, repetition time = 2.6 s, echo time = 35 ms, number of temporal dynamics = 125).

MRI pre-processing

Structural and functional MRI data were pre-processed and analysed using SPM12 (Wellcome Centre for Human Neuroimaging, London, UK) running in Matlab R2016b (The Mathworks, Natick, Massachusetts, USA). The CONN toolbox²⁰ was used to implement the pipeline, as previously described by our team.²¹ Briefly, the following pre-processing steps were applied: 1) slice-timing and realignment; 2) co-registration of structural and functional images; 3) segmentation of T1-weighted images into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) tissue maps; 4) normalisation of both T1- and T2*-weighted scans into the MNI space; and 5) smoothing of both images via a Gaussian kernel of 6 mm. Multiple denoising steps were carried out on the pre-processed T2*-weighted images: 1) regressing out the first five components of WM and CSF signals (by means of aCompCor); 2) regressing out 12 motion parameters (three rotations, three translations and their first derivative); 3) application of a band-pass filter (0.008–0.1 Hz) to remove non-neural signals; 4) linear detrending; and 5) de-spiking.

Subsequently, native-space GM, WM and CSF maps were used to extract tissue volumes (in ml) using the "get_totals" script. The volumes of the three tissues were summed to calculate total intracranial volume (TIV) for each participant.

To obtain ACh- and DA-related FC maps, all pre-processed functional scans were fed into an additional pre-processing pipeline called Receptor-Enriched Analysis of functional

Connectivity by Targets (REACT).²² First, five publicly-available PET atlases were sourced: D1 DA receptor,²³ D2 DA receptor,²⁴ vesicular ACh transporter (VAChT),²⁵ M1 muscarinic receptor²⁶ and $\alpha_4\beta_2$ nicotinic receptor.²⁷ A single-photon emission computerised tomography (SPECT) atlas was used for the DA transporter (DAT).²⁸ All of the atlases were resampled to resize the voxel dimensions of the pre-processed functional scans (i.e., 2 × 2 × 2 mm³), this was a deviation from the original REACT pipeline. Subsequently, the following atlas-specific reference regions were masked out: the cerebellum for three atlases,^{23,24,26} the occipital lobe for the atlas by Dukart et al.²⁸ and WM for the atlas by Aghourian et al.,²⁵ whereas Hillmer et al.²⁷ used no reference region methods. Finally, all atlases were normalised by setting the minimum value to zero and by rescaling the new values of each image within the range defined by the minimum and maximum values.

Before extracting the neurotransmitter-related FC maps, a set of masks was created: 6 atlasspecific masks obtained by intersecting all functional scans with each PET atlas and a publicly available GM mask (https://github.com/ottaviadipasquale/react-fmri), and a seventh, atlasindependent mask resulting from the sole intersection of all functional scans with the GM mask. These masks were used in two sequential steps at the basis of the FC extraction procedure.²² First, PET/SPECT atlases were used as spatial regressors to estimate participant-specific timeseries in the blood-oxygen-level-dependent signal fluctuations weighted by the distribution of the target neurotransmitter receptor/transporter across the whole brain. An independent model was used for each atlas. Second, the estimated time-series were used as temporal regressors to extract whole-brain neurotransmitter-related FC spatial maps for each participant. The same functional scans (resolution: $2 \times 2 \times 2$ mm³) were used in both steps, deviating from the original REACT pipeline.

Furthermore, a modified REACT pipeline was re-run to study the DA-related FC of the mesocorticolimbic and nigrostriatal pathways separately by using specific GM masks. To do

this, 2 binary GM masks were created using the WFU PickAtlas toolbox, and combining the following, literature-informed regions:²⁹⁻³¹ 1) nucleus accumbens, amygdala, hippocampus, entorhinal cortex (i.e., BA28/34), parahippocampal gyrus, cingulate gyrus, subcallosal gyrus (i.e., BA25), lateral orbitofrontal cortex, lateral and medial superior frontal gyrus, middle frontal gyrus and orbital inferior frontal gyrus were combined as mesocorticolimbic afferents; 2) caudate nucleus, putamen and globus pallidus were combined as nigrostriatal afferents. These masks were used to extract FC maps between each DA system and the entire brain.

Statistical analysis

Demographic variables, cognitive scores and global MRI volumes were compared across groups using ANOVA and Kruskal-Wallis test for normally and non-normally distributed variables, respectively. The Shapiro-Wilk test was used for preliminary checks of the normality of distributions. The chi-square test was used for categorical variables. A significance threshold of p < 0.05 was used for all analyses.

ANOVA models were implemented in SPM12 to compare neurotransmitter-related connectivity maps across all groups, and independent-sample t-tests were used for pair-wise *post hoc* comparisons. Age, education, sex, TIV and recruitment site were included as covariates in all models, and a significance cluster-forming threshold of p < 0.001 with family-wise error correction to account for multiple comparisons was used.

Finally, using SPM12, multiple regression models were used to test the association between all neurotransmitter-related FC maps and both the composite score of global cognitive performance (except for five participants with three or fewer cognitive scores) and the Logical Memory test delayed-recall score (LM-DR, except for seven participants who did not complete this test). The same covariates and significance threshold used in the between-group comparisons were applied to these regression models.

A sensitivity analysis was carried out with SPM12 to test the above-mentioned models in participants with biomarker data and comparisons were performed between A β - CU (n = 28), A β + AD-MCI (n = 13), and A β + AD-dementia (n = 16) groups, while regression models were tested on all A β + participants (n = 30, namely 13 AD-MCI, 16 AD dementia and 1 CU). Due to the limited sample size of groups with biomarkers, a significance cluster-forming threshold of p < 0.005 was used.

Results

The patient and control groups were matched for age, but CU had significantly more years of education than the AD-MCI and AD-dementia groups (Table 1). Both patient groups showed worse performance than CU in all cognitive tests, with the only exception of scores on the Digit Span forwards that did not differ between AD-MCI and CU. Moreover, the proportions of diagnostic groups differed across centres (Table 1), with considerably fewer AD-dementia patients recruited in Venice. Some participants in both patient groups were on treatment with AChEI at the time of recruitment, with a significantly higher proportion in the AD-dementia group (46%) than in the AD-MCI group (7%).

++ Please add Table 1 about here ++

The Aβ positivity status was available for 81 participants (Kuopio and Sheffield sites): 60 CSF, 2 PET and 19 blood examinations. For the 60 participants with CSF data, p-tau positivity status was also available (Table 2). No biomarker data were available for the Venice site. Both groups of patients were more likely to be positive for both Aβ and p-tau biomarkers than the CU group.

Downloaded from https://academic.oup.com/braincomms/advance-article/doi/10.1093/braincomms/fcaf008/7951367 by Brunel University London user on 22 January 2025

++ Please add Table 2 about here ++

Two ANOVA models revealed significant group differences: DAT-related FC in the right insula and thalami, and M1-related FC in the right superior/middle temporal gyri and in the left inferior parietal lobule (Table 3). Additional pair-wise models revealed DA-related FC alterations only from the analyses of the mesocorticolimbic and nigrostriatal pathways. In particular, the AD-dementia group had lower mesocorticolimbic D1-related FC than the AD-MCI group in the left precuneus but higher mesocorticolimbic DAT-related FC than CU in the bilateral thalamus (dorsolateral and mediolateral nuclei). Instead, the AD-MCI group had lower nigrostriatal DAT-related FC in the left superior temporal gyrus than the CU group. Compared with CU, lower M1-related FC was observed in AD-MCI in a cluster limited to the right superior/middle temporal gyri, and this also extended to both inferior parietal lobules in AD dementia (Table 3 and Figure 1). Finally, VAChT-related FC was also found to be lower in the right postcentral (BA 2 and 3) and precentral (BA 6) gyri in the AD-MCI group than in the CU group.

++ Please add Table 3 and Figure 1 about here ++

Regression analysis found that the cognitive composite score was positively associated with M1-related FC in the right superior/middle temporal, right cerebellar (culmen) and bilateral posterior cingulate areas (Table 4 and Figure 2). Variegated associations were observed between episodic memory performance and FC. Indeed, in the mesocorticolimbic pathway, LM-DR scores were negatively associated with D1-related FC in left middle/inferior frontal cortices and DAT-related FC in bilateral anterior cingulate and thalamus (i.e., the dorsolateral nucleus), and positively associated with DAT-related FC in the bilateral precuneus/posterior

cingulate. Moreover, episodic memory performance was also negatively associated with nigrostriatal D2-related FC in the left occipito-temporal area. For the cholinergic system, LM-DR scores were positively associated with VAChT-related FC in the right postcentral gyrus and left occipito-temporal areas and with M1-related FC in the bilateral inferior parietal and right superior/middle temporal cortices. However, a negative association was also found with M1-related FC in left-lateralised superior/middle frontal areas (Table 4).

++ Please add Table 4 about here and Figure 2 ++

Some of the above findings were replicated in the sensitivity analyses. M1-related FC in the right posterior middle temporal gyrus was lower in the A β + AD-dementia group than in the A β - CU group (Figure 3 and Table 5). Episodic LM-DR scores were positively correlated with M1-related FC in a cluster comprising the right fusiform gyrus and the right cerebellum in A β + participants. A novel finding emerged that was not highlighted in the main analysis: lower $\alpha_4\beta_2$ -related FC in A β + AD-MCI than in the A β - CU group in the right lingual gyrus and the left posterior cingulate cortex (Figure 3 and Table 5). No between-group differences or cognition-FC associations were found in the DA systems.

++ Please add Table 5 about here and Figure 3 ++

Discussion

This study found that, along with ACh-related FC alterations, DA-related FC changes may be detected in both the AD-MCI and AD-dementia groups only when dopaminergic pathways were investigated separately. However, when analyses were restricted to patients with available

evidence of AD pathological changes (i.e., $A\beta$ + status), the only neurofunctional alterations evident in both patient groups were those associated with the cholinergic system. In the mesocorticolimbic pathway, the AD-dementia group showed lower D1-related FC than the AD-MCI group in the left precuneus and higher DAT-related FC than the CU group in the thalamus. The former finding suggests a decline in FC between the target areas of the mesocorticolimbic pathway and the posterior DMN in AD dementia mediated by the distribution of the D1 receptor. This seems to be in line with a previous observation of weaker FC between the VTA and the posterior DMN.¹⁰ In fact, the DMN includes a posterior hub

comprising the precuneus and the posterior cingulate cortex³² that has long been established to be dysregulated in AD.^{33,34} It is possible that the FC decline observed in the clinical progression from AD-MCI to AD-dementia might be mediated by dopaminergic dysfunction evident between the mesocorticolimbic system and the posterior DMN. Although no data are available for AD, the cerebral distribution of the D1 receptor has been linked to the gradient-based brain organisation, particularly to greater functional differentiation between the DMN and the sensory cortices.³⁵ The findings of the present study suggest a breakdown in the communication between the mesocorticolimbic system and the DMN. In line with this view, the regression analyses showed a positive association between mesocorticolimbic DAT-related FC in the posterior DMN and episodic memory performance, the most severely affected function in the AD clinical continuum. However, the cross-sectional design of this study prevented any conclusions from being drawn on the dynamic evolution of FC in this pathway over time. Moreover, D1-related FC alterations emerged only when the AD-dementia group was compared with AD-MCI participants, but not when compared with the CU group. Therefore, it cannot be ruled out that these findings might be a consequence of divergent sub-threshold FC differences between the two patient groups and CU older adults (i.e., higher FC at the AD-MCI stage and lower FC at the AD-dementia stage).

DAT-related FC, by contrast, was heightened between the mesocorticolimbic system and the thalamus in the AD-dementia group when compared with CU. This was found in the laterodorsal nucleus and, to a lesser extent, the mediodorsal nucleus of the thalamus bilaterally. The laterodorsal nucleus is connected primarily with the restrosplenial, mediotemporal and occipital areas,³⁶ is involved in memory functions and is particularly atrophic in AD,³⁷ In contrast, the mediodorsal nucleus is connected to the temporal and prefrontal areas and is typically affected by AD pathology to a lesser extent than the laterodorsal nucleus.³⁸ As episodic memory performance was negatively associated with DAT-related FC between the mesocorticolimbic system and both these thalamic nuclei and the anterior cingulate cortex, such alterations are suggestive of maladaptive plasticity.³⁹ Similar negative associations between the LM-DR scores and D1-related FC in left middle and inferior frontal areas further support this interpretation. Alternatively, it may be possible that heightened mesocorticolimbic DA-related FC in fronto-thalamic areas, known to be involved in executive processes,⁴⁰ plays a temporary compensatory role by supporting memory pathways in an attempt to cope with inefficient retrieval in people with MCI and mild AD-dementia. Indeed, recent evidence has accumulated to suggest a prominent role of the mediodorsal nucleus in regulating frontal lobe activation when required over an extended period of time.⁴¹

These findings seem to contradict those of De Marco & Venneri,⁹ who found that stronger FC between the VTA and prefrontal areas was associated with better episodic memory. However, there are some methodological differences between the two studies that may limit comparisons of findings. In contrast to De Marco & Venneri,⁹ this study investigated FC weighted using specific PET atlases and focussed on the cortical and subcortical targets of the mesocorticolimbic pathway rather than on the VTA. It cannot be ruled out, however, that degeneration of the VTA may induce divergent FC changes in the VTA itself and in the cerebral regions innervated by its projections.

The findings related to the nigrostriatal system were, overall, inconsistent. Lower DAT-related FC was observed in the left temporal pole in the AD-MCI group than in the CU group but was not replicated in the AD-dementia group. In contrast, the regression models indicated a positive association between episodic memory scores and D2-related FC in the retrosplenial and temporo-occipital regions.^{42,43} Although heterogeneous, these results suggest that clinical AD stages may also result in alterations in nigrostriatal DA-related FC in left-lateralised areas known to support verbal memory.^{44,45}

The above-mentioned findings were not replicated in sensitivity analyses carried out on the patient groups with evidence of $A\beta$ + status. There are two main reasons for this lack of replication. First, DA pathways may be altered in AD but to a lesser extent than in the cholinergic system.² DA dysfunction could either be a secondary process or occur at a later stage in the aetiopathogenesis of AD compared with ACh alterations. Second, the small number of participants with available biomarkers strongly limited the sample size of the groups included in the sensitivity analysis that may have been under-powered to detect small effects. In contrast, neurofunctional alterations in the cholinergic system appeared to be more robust, especially those related to the M1 receptor. When compared with CU, the AD-MCI group had lower M1-related FC in the right-lateralised temporal areas, while the AD-dementia group showed lower FC in the bilateral temporo-parietal cortices, including the inferior parietal lobule that is part of the DMN.³² These findings were replicated in the sensitivity analysis, although lower M1-related FC in the right middle temporal gyrus was only observed in the A β + ADdementia group when compared with the A β - CU group. This pattern suggests that gradual worsening of M1-related FC in posterior temporal areas may parallel the clinical progression of AD, since better global cognition and episodic memory performance was positively associated with M1-related FC in the temporal, inferior parietal and posteromedial areas, bilaterally. In A β + participants, this association persisted in a smaller cluster between the right

fusiform gyrus and the declive of the cerebellum. Previous studies have found reduced M1 receptor density in patients with AD, compared with CU older adults, primarily in medio-posterior temporal and limbic areas and associated with reduced perfusion and longer disease duration.⁴⁶⁻⁴⁹ All these sources of evidence suggest that cholinergic dysfunction mediated by the M1 receptor is evident in areas heavily affected by AD pathology such as the posterior and inferior temporal regions.

VAChT-related FC was lower among individuals with AD-MCI than among those with CU in a small right-lateralised sensorimotor cluster. Episodic memory was also positively associated with higher VAChT-related FC in the right somatosensory cortex, but also with regions identified by the analysis of dopaminergic pathways, i.e., the left occipito-temporal cortex and left BA23. The clinical relevance of this finding, however, is uncertain, since sensorimotor areas are neither rich in VAChT²⁵ nor particularly affected by AD pathology and the findings have not been replicated in the sensitivity analysis. Given the relative sparing of sensory neural structures at the disease stages investigated in the present study, these findings might reflect compensatory over-recruitment of these neural structures in support of neighbouring failing systems to support behavioural performance.

Lower $\alpha_4\beta_2$ -related FC in A β + AD-MCI than in the A β - CU group in the right lingual gyrus and the left posterior cingulate cortex was only found in the sensitivity analysis, thus further strengthening the suggestion that ACh depletion can trigger malfunctioning in the posterior temporo-parietal cortices clinically relevant to AD. As for VAChT-related FC, also this result remains difficult to interpret because no differences were found between the AD-dementia and CU groups. This could be due to a lack of statistical power given the smaller sample size of the AD-dementia group compared with the AD-MCI group. A possible alternative explanation could be that a considerable number of people with AD dementia were treated with AChEIs (27 out of 58). Such pharmacological treatment might have induced adjustments in the

cholinergic system to such an extent that it reduced alterations in resting-state activity secondary to ACh depletion, as found in previous studies of patients treated with Donepezil.^{50,51} However, the small number of treated patients and the lack of longitudinal MRI data for this sample prevent any more specific investigation of the nature of these effects unbiased by unknown variables.

The convergence of findings in this study suggests that clinical severity of AD is primarily associated with FC decline in the posterior DMN and in temporal areas (typically affected by AD pathology) and, potentially, with FC increase in fronto-thalamic areas. Research on CU adults found that the basal forebrain (i.e., the main source of ACh) suppresses DMN activation, while the mediodorsal thalamic nucleus increases it.⁵² As the lack of DMN deactivation has been extensively documented in AD,⁵³ FC alterations associated with the distribution of the M1 receptor may represent clinically informative resting-state fMRI markers of AD severity. M1 receptor density is maximal in the ventral striatum, innervated by the VTA,^{30,31} and in the temporal and posterior DMN areas.^{26,54} Additionally, the M1 receptor is functionally relevant to memory processes⁵⁵ and its dysregulation appears to be linked to AD pathological processes.⁵⁶ Alterations in the M1/M4 receptor distribution may be associated with the duration of cognitive symptoms, while symptom severity in AD appears to be accounted for by neurofunctional changes in the temporal and posterior DMN areas.⁴⁶ The M1 receptor appears to be an ideal candidate target for potential treatments aimed at slowing the progression of cognitive decline in AD whose mechanism of action could be easily tested by means of the method utilised in this study (i.e. REACT). Similarly, mesocorticolimbic DAT-related FC may also offer potential insights into AD pathological changes since mesocorticolimbic DAT reductions have been reported to be more severe than in the nigrostriatal pathway¹³ and lower CSF levels of DAT have been associated with hypometabolism in the posterior DMN in AD.⁵⁷

Page 19 of 40

This study had some limitations. First, PET scans were not available, thus preventing any conclusion on the potential impact of AD-induced neurotransmitter alterations on brain function. Second, not all receptors for the DA and ACh neurotransmitters could be assessed because of the current lack of established PET ligands. Furthermore, overlaps between the neural territories innervated by ACh- and DA-producing nuclei are well-known, but the risk of confounding effects is minimised by the use of receptor- and transport-specific voxel-based density maps. Third, this study focussed only on DA and Ach; however, other neurotransmitters are affected by AD pathological processes, such as noradrenaline. In fact, the locus coeruleus seems to be vulnerable to hyperphosphorylated tau accumulation in preclinical stages of AD.⁵⁸ Fourth, the design of this study was cross-sectional, thus limiting the interpretation of these findings regarding the longitudinal evolution of neurofunctional alterations across the AD continuum. Fifth, only a proportion of the patients included in this study had AD biomarkers to support clinical diagnoses, as patients were recruited before the publication of the AT(N) research framework.¹ Particular care was taken to ensure that, not only did they meet criteria for clinical diagnosis of AD-MCI¹⁴ or AD-dementia,¹⁵ but also that they all had an extensive follow up indicating clinical progression in line with an AD aetiology. Finally, although culturally diverse, the sample of this study was predominantly ethnically homogenous. Future studies should aim to improve inclusivity practices to enable the recruitment of diverse and representative cohorts to improve replication and generalisability of these findings.

This study represents the first investigation of neurotransmitter-related functional alterations in individuals with MCI and mild dementia due to AD. These findings suggest that combining *a priori* knowledge of the distribution of specific neurotransmitters (via PET atlases) with advanced MRI processing techniques may lead to the generation of clinically informative biomarkers for AD. Such biomarkers may be useful to track symptom changes (both in

cognition and behaviour) over time, characterise specific phenotypes (e.g. one study applied REACT to characterise the neural correlates of cognitive fatigue in people with multiple sclerosis⁵⁹) and provide insights for treatment targets. Indeed, previous studies have highlighted how the REACT technique can detect pharmacologically induced FC changes related to specific neurotransmitter systems known to be modulated by specific medications (e.g. 3,4methylenedioxymethamphetamine serotonin²², methylphenidate and and dopamine/noradrenaline transporters⁶⁰, and lysergic acid diethylamide and dopamine and serotonin⁶¹). Such FC changes were also associated with drug-evoked behavioural responses. Furthermore, this approach might have prognostic implications in those CU individuals who are biomarker-positive but do not manifest any subjective or objective symptoms of cognitive change. An additional application of this approach would aid in distinguishing individuals with MCI who are likely to progress to AD-dementia from those with MCI caused by other conditions. Future research should also address whether confounding factors, such as lifestyle (e.g type of diet), drug use and smoking, might have a significant impact on neurotransmitterrelated FC in order to disentangle the effects of neurodegeneration from those of modifiable risk factors. A further fruitful development would be the design of much needed hypothesisdriven neuroimaging outcome measures to test the mechanisms of action of new pharmacological interventions for AD. This appears to be particularly timely in the new era of disease-modifying treatments as well as to explore new avenues towards a cure for AD.

Data availability

The data supporting the findings of this study are available from the corresponding author, upon reasonable request.

Funding

AV and RM are supported by funding obtained under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3 - Call for tender No. 341 of 15/03/2022 of Italian Ministry of University and Research funded by the European Union – NextGenerationEU, Project code PE0000006, Concession Decree No. 1553 of 11/10/2022 adopted by the Italian Ministry of University and Research, CUP D93C22000930002, "A multiscale integrated approach to the study of the nervous system in health and disease" (MNESYS).

This work was supported by funding from the Excellent Science 2022 call of the University of Parma under the Fund for the Promotion and Development of the Policies of the National Research Programme awarded to AV.

The dataset used in this study was collected as part of a project supported by funding from the European Union Seventh Framework Program (FP7/2007e2013) under grant agreement no. 601055, Virtual Physiological Human: DementiA RESearch Enabled by IT (VPH-DARE@IT) to AV and HS.

Competing interests: The authors report no competing interests.

References

 1. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.018

2. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to
Alzheimer's disease. *Ann Neurol.* 2001;49(1):53–66. doi:10.1002/15318249(200101)49:13.0.co;2-q

3. Rossor MN. Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core. *Br Med J (Clin Res Ed)*. 1981;283(6306):1588–1590. doi:10.1136/bmj.283.6306.1588

4. Stratmann K, Heinsen H, Korf H, et al. Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology. *Brain Pathol.* 2016;26(3):371–386. doi:10.1111/bpa.12289

5. Mesulam M-. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. *J Comp Neurol.* 2013;521(18):4124–4144. doi:10.1002/cne.23415

6. Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. *Ann Neurol.* 2000;48(2):194–200

7. Cordella A, Krashia P, Nobili A, et al. Dopamine loss alters the hippocampus-nucleus accumbens synaptic transmission in the Tg2576 mouse model of Alzheimer's disease. *Neurobiol Dis.* 2018;116:142–154. doi:10.1016/j.nbd.2018.05.006

8. Nobili A, Latagliata EC, Viscomi MT, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. *Nat Commun.* 2017;8:14727. doi:10.1038/ncomms14727

9. De Marco M, Venneri A. Volume and Connectivity of the Ventral Tegmental Area are Linked to Neurocognitive Signatures of Alzheimer's Disease in Humans. *J Alzheimers Dis.* 2018;63(1):167–180. doi:10.3233/JAD-171018

10. Serra L, D'Amelio M, Di Domenico C, et al. In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. *Neurobiol Aging*. 2018;72:72–82. doi:10.1016/j.neurobiolaging.2018.08.012

11. Venneri A, De Marco M. Reduced monoaminergic nuclei MRI signal detectable in presymptomatic older adults with future memory decline. *Sci Rep.* 2020;10(1):18707. doi:10.1038/s41598-020-71368-1

12. Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility assessment of neuromelaninsensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. *Neuroimage*. 2020;208:116457. doi:10.1016/j.neuroimage.2019.116457

13. Sala A, Caminiti SP, Presotto L, et al. In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. *Alzheimers Res Ther.* 2021;13(1):187. doi:10.1186/s13195-021-00925-1

14. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7(3):270–279. doi:10.1016/j.jalz.2011.03.008

15. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263–269. doi:10.1016/j.jalz.2011.03.005

16. Jones SA, De Marco M, Manca R, et al. Altered frontal and insular functional connectivity as pivotal mechanisms for apathy in Alzheimer's disease. *Cortex*. 2019;119:100–110. doi:10.1016/j.cortex.2019.04.008

17. Wechsler D. Wechsler Adult Intelligence Scale--Fourth Edition (WAIS-IV). NCS Pearson;2008

18. Lezak MD. Neuropsychological Assessment. 3rd ed. Oxford University Press; 2004

19. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. A short version of the Stroop test: normative data in an Italian population sample [Una versione abbreviata del test di Stroop: dati normativi nella popolazione Italiana]. *Riv Neurol.* 2002;12(4):111–115

20. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. *Brain Connect.* 2012;2(3):125–141. doi:10.1089/brain.2012.0073

21. Manca R, Khan K, Mitolo M, et al. Modulatory effects of cognitive exertion on regional functional connectivity of the salience network in women with ME/CFS: A pilot study. *J Neurol Sci.* 2021;422:117326. doi:10.1016/j.jns.2021.117326

22. Dipasquale O, Selvaggi P, Veronese M, Gabay AS, Turkheimer F, Mehta MA. Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA. *Neuroimage*. 2019;195:252–260. doi:10.1016/j.neuroimage.2019.04.007

23. Kaller S, Rullmann M, Patt M, et al. Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. *Eur J Nucl Med Mol Imaging*. 2017;44(6):1025–1032. doi:10.1007/s00259-017-3645-0

24. Sandiego CM, Gallezot J, Lim K, et al. Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET. *J Cereb Blood Flow Metab*. 2015;35(4):623–629. doi:10.1038/jcbfm.2014.237

25. Aghourian M, Legault-Denis C, Soucy J-, et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. *Mol Psychiatry*. 2017;22(11):1531–1538. doi:10.1038/mp.2017.183

26. Naganawa M, Nabulsi N, Henry S, et al. First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. *J Nucl Med.* 2021;62(4):553–560. doi:10.2967/jnumed.120.246967

27. Hillmer AT, Esterlis I, Gallezot JD, et al. Imaging of cerebral $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *Neuroimage*. 2016;141:71–80. doi:10.1016/j.neuroimage.2016.07.026

28. Dukart J, Holiga Š, Chatham C, et al. Cerebral blood flow predicts differential neurotransmitter activity. *Sci Rep.* 2018;8(1):4074. doi:10.1038/s41598-018-22444-0

29. Steidel K, Ruppert MC, Palaghia I, et al. Dopaminergic pathways and resting-state functional connectivity in Parkinson's disease with freezing of gait. *Neuroimage Clin.* 2021;32:102899. doi:10.1016/j.nicl.2021.102899

30. Iaccarino L, Sala A, Caminiti SP, Presotto L, Perani D. In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimer's Disease. *J Alzheimers Dis*. 2020;75(3):1003–1016. doi:10.3233/JAD-190954

31. Coenen VA, Schumacher LV, Kaller C, et al. The anatomy of the human medial forebrain bundle: Ventral tegmental area connections to reward-associated subcortical and frontal lobe regions. *Neuroimage Clin.* 2018;18:770–783. doi:10.1016/j.nicl.2018.03.019

32. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. *Proc Natl Acad Sci U S A*. 2001;98(2):676–682. doi:10.1073/pnas.98.2.676

33. Koch W, Teipel S, Mueller S, et al. Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. *Neurobiol Aging*. 2012;33(3):466–478. doi:10.1016/j.neurobiolaging.2010.04.013

34. Jones DT, Machulda MM, Vemuri P, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. *Neurology*. 2011;77(16):1524–1531. doi:10.1212/WNL.0b013e318233b33d

35. Pedersen R, Johansson J, Nordin K, et al. Dopamine D1-Receptor Organization Contributes
to Functional Brain Architecture. *J Neurosci.* 2024;44(11):e0621232024.
doi:10.1523/JNEUROSCI.0621-23.2024

36. Perry BAL, Mitchell AS. Considering the Evidence for Anterior and Laterodorsal Thalamic Nuclei as Higher Order Relays to Cortex. *Front Mol Neurosci.* 2019;12:167. doi:10.3389/fnmol.2019.00167

37. Iglesias JE, Insausti R, Lerma-Usabiaga G, et al. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. *Neuroimage*. 2018;183:314–326. doi:10.1016/j.neuroimage.2018.08.012

38. Zarei M, Patenaude B, Damoiseaux J, et al. Combining shape and connectivity analysis: an MRI study of thalamic degeneration in Alzheimer's disease. *Neuroimage*. 2010;49(1):1–8. doi:10.1016/j.neuroimage.2009.09.001

39. Penalba-Sánchez L, Oliveira-Silva P, Sumich AL, Cifre I. Increased functional connectivity patterns in mild Alzheimer's disease: A rsfMRI study. *Front Aging Neurosci*. 2023;14:1037347. doi:10.3389/fnagi.2022.1037347

40. Boeken OJ, Cieslik EC, Langner R, Markett S. Characterizing functional modules in the human thalamus: coactivation-based parcellation and systems-level functional decoding. *Brain Struct Funct.* 2023;228(8):1811–1834. doi:10.1007/s00429-022-02603-w

41. Pergola G, Danet L, Pitel A, et al. The Regulatory Role of the Human Mediodorsal Thalamus. *Trends Cogn Sci.* 2018;22(11):1011–1025. doi:10.1016/j.tics.2018.08.006

42. Cabeza R, Nyberg L. Neural bases of learning and memory: functional neuroimaging evidence. *Curr Opin Neurol.* 2000;13(4):415–421. doi:10.1097/00019052-200008000-00008

43. Maguire EA. The retrosplenial contribution to human navigation: a review of lesion and neuroimaging findings. *Scand J Psychol.* 2001;42(3):225–238. doi:10.1111/1467-9450.00233

44. Herlin B, Navarro V, Dupont S. The temporal pole: From anatomy to function-A literature appraisal. *J Chem Neuroanat*. 2021;113:101925. doi:10.1016/j.jchemneu.2021.101925

45. Liang X, Yuan Q, Xue C, et al. Convergent functional changes of the episodic memory impairment in mild cognitive impairment: An ALE meta-analysis. *Front Aging Neurosci*. 2022;14:919859. doi:10.3389/fnagi.2022.919859

46. Colloby SJ, McKeith IG, Wyper DJ, O'Brien JT, Taylor J. Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT. *J Neurol.* 2015;262(9):2144–2153. doi:10.1007/s00415-015-7827-z

47. Pakrasi S, Colloby SJ, Firbank MJ, et al. Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. *J Neurol.* 2007;254(7):907–913. doi:10.1007/s00415-006-0473-8

48. Overk CR, Felder CC, Tu Y, et al. Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. *J Chem Neuroanat*. 2010;40(1):63–70. doi:10.1016/j.jchemneu.2010.03.005

49. Weinberger DR, Gibson R, Coppola R, et al. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. *Arch Neurol.* 1991;48(2):169–176. doi:10.1001/archneur.1991.00530140061018

50. Goveas JS, Xie C, Ward BD, et al. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. *J Magn Reson Imaging*. 2011;34(4):764–773. doi:10.1002/jmri.22662

51. Griffanti L, Wilcock GK, Voets N, et al. Donepezil Enhances Frontal Functional Connectivity in Alzheimer's Disease: A Pilot Study. *Dement Geriatr Cogn Dis Extra*.
2016;6(3):518–528. doi:10.1159/000450546

52. Harrison BJ, Davey CG, Savage HS, et al. Dynamic subcortical modulators of human default mode network function. *Cereb Cortex*. 2022;32(19):4345–4355. doi:10.1093/cercor/bhab487

53. Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. *Nat Rev Neurosci.* 2016;17(12):777–792. doi:10.1038/nrn.2016.141

54. Hansen JY, Shafiei G, Markello RD, et al. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. *Nat Neurosci*. 2022;25(11):1569–1581. doi:10.1038/s41593-022-01186-3

55. Abrams P, Andersson K, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. *Br J Pharmacol.* 2006;148(5):565–578. doi:10.1038/sj.bjp.0706780

56. Jiang S, Li Y, Zhang C, et al. M1 muscarinic acetylcholine receptor in Alzheimer's disease. *Neurosci Bull.* 2014;30(2):295–307. doi:10.1007/s12264-013-1406-z

57. Camedda R, Bonomi CG, Di Donna MG, Chiaravalloti A. Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer's Disease: A Preliminary 18F-FDG PET/CT Study. *Int J Mol Sci.* 2023;24(1):751. doi:10.3390/ijms24010751

58. Van Egroo M, Riphagen JM, Ashton NJ, et al. Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau. *Mol Psychiatry*. 2023:1–11. doi:10.1038/s41380-023-02041-y

59. Cercignani M, Dipasquale O, Bogdan I, et al. Cognitive fatigue in multiple sclerosis is associated with alterations in the functional connectivity of monoamine circuits. *Brain Commun.* 2021;3(2):fcab023. doi:10.1093/braincomms/fcab023

60. Dipasquale O, Martins D, Sethi A, et al. Unravelling the effects of methylphenidate on the dopaminergic and noradrenergic functional circuits. *Neuropsychopharmacology*. 2020;45(9):1482–1489. doi:10.1038/s41386-020-0724-x

61. Lawn T, Dipasquale O, Vamvakas A, Tsougos I, Mehta MA, Howard MA. Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD. *Psychopharmacology (Berl)*. 2022;239(6):1797–1808. doi:10.1007/s00213-022-06117-5

Variable	CU (<i>n</i> = 76)	AD-MCI (n = 86)	AD-dementia (n = 58)	F	p
Ageª	69.5 (12.3)	72.5 (15.8)	68.0 (17.5)	2.07 ^b	0.355
Education	13.6 (3.3)	11.4 (3.7)	11.4 (3.4)	9.82	< 0.001
Sex (M/F) ^c	29/47	36/50	28/30	1.39 ^d	0.499
MMSE ^a	29.0 (1.2)	27.0 (3.0)	21.0 (6.7)	97.26 ^b	< 0.001
LM-IR	0.0 (1.0)	-1.8 (1.4)	-3.2 (1.3)	129.23	< 0.001
LM-DR	0.0 (1.0)	-2.4 (2.0)	-4.8 (2.0)	147.82	< 0.001
PF	0.0 (1.0)	-0.6 (1.3)	-1.2 (1.1)	21.28	< 0.001
ST - time	0.0 (1.0)	1.5 (2.4)	1.6 (3.6)	17.45	< 0.001
DS-F	0.0 (1.0)	-0.4 (1.0)	-0.7 (1.1)	8.27	< 0.001
DS-B	0.0 (1.0)	-0.7 (0.8)	-1.1 (1.1)	17.94	< 0.001
Similarities	0.0 (1.0)	-1.2 (1.5)	-2.4 (2.0)	36.51	< 0.001
Composite score	0.0 (0.5)	-0.8 (0.8)	-1.7 (0.9)	82.39	< 0.001
TIV	1452.1 (166.2)	1441.3 (139.2)	1451.9 (152.0)	0.14	0.871
GMV ^a	612.3 (99.9)	600.3 (91.9)	548.5 (114.0)	21.25 ^b	< 0.001
AChEI (n. treated)	0	6	27	63.04 ^d	< 0.001
Site (S1/S2/S3) ^{c,e}	18/37/21	43/27/16	27/28/3	20.6 ^d	< 0.001

Table 1 Clinical profiles of the participant groups (values are means and standard deviations and statistical models are ANOVAs unless otherwise specified)

AChEI: Acetylcholinesterase inhibitors; AD: Alzheimer's disease; CU: Cognitively unimpaired; DR: Delayed recall; DS-F/B: Digit Span – Forwards/Backwards; F: Females; GMV: Grey matter volume; IR: Immediate recall; LM: Logical memory; M: Males; MCI: Mild cognitive impairment; MMSE: Mini Mental State Examination; PF: Phonemic fluency; S1/S2/S3: Site 1/2/3; ST: Stroop test; TIV: Total intracranial volume

^a Values are medians and interquartile ranges

^b Kruskal–Wallis test

^c Values are frequencies

^d Chi-square test

^e Site 1 = Kuopio; Site 2 = Sheffield; Site 3 = Venice

In bold, significant differences in the post hoc tests comparison with unimpaired controls

	ble	CU	AD-MCI	AD-dementia	χ²	р
AB sta	atus	<i>n</i> = 29	<i>n</i> = 20	<i>n</i> = 32	23.04	< 0.00
•	Αβ+	1	13	16		
•	Αβ-	28	7	16		
p-tau	status	<i>n</i> = 18	<i>n</i> = 19	<i>n</i> = 23	8.94	0.011
•	p-tau+	2	10	12		
•	p-tau-	16	9	11		
 ιβ: am n bold	p-tau- yloid beta; AD: , significant dif	16 Alzheimer's disease; fferences in the <i>post h</i>	9 CU: Cognitively unimpa <i>oc</i> tests comparison wi	11 aired; p-tau: Phosphor ith unimpaired contro	rylated tau Is	Ś
					55	

Table 3 Differences in neurotransmitter-enriched functional connectivity across groups

Contrast	p-value	Cluster size	Side	Brain region	t value	MNI coordinates		
	-			5		x	v	z
		Mesocort	icolimbic	<i>pathway</i> : Dopamine - D1			-	
AD-MCI < AD- dementia	0.017	144	L	Precuneus (BA7)	4.71	-2	-63	49
			L	Precuneus (BA7)	4.47	0	-69	54
		Mesocorti	colimbic	<i>pathway</i> : Dopamine - DAT				
ANOVA ^a	0.010	72	R	Insula (BA13)	14.08	30	16	13
	0.003	92	R	Thalamus	12.72	6	-18	18
			L	Thalamus	9.93	-2	-14	19
AD-dementia > CU	0.004	156	R	Thalamus	4.36	6	-18	18
			L	Thalamus	4.28	-2	-14	19
		Nigrost	riatal pa	thway: Dopamine - DAT		- A		
AD-MCI < CU	0.031	134	Ľ	STG (BA38)	4.67	-25	9	-39
			L	STG (BA38)	4.20	-39	15	-38
			Acety	Icholine - M1				
ANOVA ^a	< 0.001	688	R	STG (BA22)	14.59	61	-43	10
			R	MTG (BA21)	13.50	55	-35	-5
			R	MTG (BA21)	12.98	57	-25	-9
	0.007	125	L	IPL (BA40)	12.30	-61	-42	33
			L	IPL (BA40)	11.46	-65	-38	27
AD-MCI < CU	0.001	371	R	STG (BA2)	4.42	47	-22	-13
			R	STG (BA22)	4.33	63	-45	6
			R	MTG (BA21)	4.18	59	-18	-11
AD-dementia < CU	< 0.001	1008	R	STG (BA22)	5.40	59	-43	10
			R	MTG (BA21)	4.73	59	-25	-9
			R	STG (BA22)	4.68	49	-39	7
	0.007	261	I	IPL (BA40)	4 78	-65	-38	27
			Ĺ	IPL (BA40)	4.25	-53	-46	31
			Acetyle	holine - VAChT				
AD-MCI < CU	0.017	236	R	Precentral gyrus (BA6)	4.15	43	-9	62
			R	Postcentral gyrus (BA2)	3.92	49	-29	55
			R	Postcentral gyrus (BA3)	3.79	53	-15	55

AD: Alzheimer's disease; BA: Brodmann area; CU: Cognitively unimpaired; D1: D1 dopamine receptor; DAT: Dopamine transporter; IPL: Inferior parietal lobule; L: Left; M1: M1 muscarinic acetylcholine receptor; MCI: Mild cognitive impairment; MTG: Middle temporal gyrus; R: Right; STG: Superior temporal gyrus; VAChT: Vesicular acetylcholine transporter ^a F values are displayed for ANOVA.

Page 33 of 40

1

2
3
4
5
6
7
8
9
10
10
11
12
13
14
15
16
17
18
10
20
∠∪ 21
21
22
23
24
25
26
27
27
20
29
30
31
32
33
34
35
36
20
27
38
39
40
41
42
43
44
45
75 76
40
4/
48
49
50
51
52
53
51
54
22
56
57
58

59 60

Table 4 Associations between neurotransmitter-enriched functional connectivity and both global cognitive and episodic
memory performance

Association	p-value	Cluster size	Side Brain region		t value	MNI coordinates		
						x	У	z
				Cog-CS				
			Acet	ylcholine - M1				
Positive	< 0.001	1148	R	STG (BA13)	5.12	55	-44	22
			R	STG (BA41)	4.73	47	-39	11
			R	MTG (BA21)	4.48	53	-35	-5
	0.026	213	R	PCC (BA29)	4.95	7	-45	15
			R	PCC (BA31)	4.07	5	-40	27
			L	PCC (BA23)	4.02	-9	-32	29
	0.001	389	R	Cerebellum – culmen	4.53	21	-50	-20
			R	Cerebellum – culmen	4.41	17	-54	-14
			R	Cerebellum – culmen	4.03	3	-56	-10
			EPIS	ODIC MEMORY				Y
		Mesoco	rticolimbi	<i>ic pathway</i> : Dopamine – D1				1
Negative	0.015	168	L	MFG (BA9)	4.74	-52	19	36
			L	MFG (BA46)	4.09	-50	28	27
			L	IFG (BA45)	3.55	-58	13	22
		Mesocor	ticolimbi	<i>c pathway</i> : Dopamine – DAT				
Positive	< 0.001	405	R	PCC (BA31)	4.58	5	-51	28
			L	Precuneus (BA7)	4.51	-11	-63	35
			L	PCC (BA31)	4.43	-21	-62	21
Negative	0.001	354	R	ACC (BA24)	5.77	2	19	29
5			L	ACC (BA32)	4.33	-4	36	23
			R	ACC (BA32)	4.01	14	18	39
	0.012	213	R	Thalamus	4.77	4	-18	18
			L	Thalamus	4.20	-2	-12	19
		Niar	ostriatal r	pathway: Dopamine – D2				
Positive	0.028	173	Ľ	Cuneus (BA23)	5.06	-15	-73	6
			L	Lingual gyrus (BA18)	4.00	-7	-71	4
			Ī	RSC (BA30)	3 75	1	-69	4
			Acet	vicholine - M1	0170	-	00	
Positive	< 0.001	1159	R	IPL (BA40)	5.93	57	-44	22
			R	STG (BA22)	4.77	61	-43	10
			R	MTG (BA22)	4,31	59	-47	2
	0.035	222		IPL (BA40)	4,51	-65	-36	29
	0.000			IPL (BA40)	416	-53	-46	31
			Ī	IPL (BA40)	3 72	-59	-38	39
Negative	0.026	241	· -	SEG (BA10)	416	-21	50	24
Negative	0.020	2.11	1	MEG (BA10)	3.96	-11	59	13
			1	SEG (BA10)	3.87	-17	58	21
			_ ∆cetvl	choline – VAChT	5.07	17	50	21
Positive	0.017	285			475	-5	-77	11
i Ositive	0.017	/ 205	1		д 1 Q	_5	_82	10
			L 	Lingual gyrus (BA18)	3 38	_9 _9	-67	2
	0.016	201	P	Postcentral avrus (BA10)	5.50 Д 5Л	- <i>9</i> 52	_20	∠ 21
	0.010	231	D	Postcentral gyrus (BA43)	4.54 1.27	55	-20	21 16
			r\ D	Postcentral gyrus (PA43)	4.52 110	57	-0 _22	22 TO
			Ń	FUSICEITIAI YYTUS (DAZ)	4.10	57	-22	33

ACC: Anterior cingulate cortex; BA: Brodmann area; D1: D1 dopamine receptor; D2: D2 dopamine receptor; DAT: Dopamine transporter; IFG: Inferior frontal gyrus; IPL: Inferior parietal lobule; L: Left; M1: M1 muscarinic acetylcholine receptor; MFG: Middle frontal gyrus; MTG: Middle temporal gyrus; PCC: Posterior cingulate cortex; R: Right; RSC: Retrosplenial cortex; SFG: Superior frontal gyrus; STG: Superior temporal gyrus; VAChT: Vesicular acetylcholine transporter

Table 5 Results of the sensitivity analysis

_

p-value Cluster size		Side Brain region		<i>t</i> value	MNI coordinates		
					x	у	z
		Ace	tylcholine – $\alpha_4\beta_2$: A β + AD-MCI < A β - CU				
0.013	354	R	Lingual gyrus (BA18)	3.57	11	-77	3
		R	Lingual gyrus (BA17)	3.57	5	-89	-3
		L	Posterior cingulate cortex (BA 30)	3.38	-1	-71	8
		Acety	choline – M1: A6+ AD-dementia < A6- C	:U			
0.027	330	R	Middle temporal gyrus (BA 21)	4.29	63	-45	-4
		R	Middle temporal gyrus (BA 22)	4.24	63	-35	-1
		R	Middle temporal gyrus (BA 21)	3.88	53	-35	-3
	Acetylc	holine – M	1: positive association with LM-DR in AB	+ participants			
0.010	349	R	Cerebellum- declive	5.36	7	-80	-19
		R	Fusiform gyrus (BA 19)	4.86	37	-70	-21
		R	Cerebellum- declive	4.60	16	-82	-21

AD: Alzheimer's disease; BA: Brodmann area; CU: Cognitively unimpaired; L: Left; M1: M1 muscarinic acetylcholine receptor; LM-DR: Logical Memory – delayed recall; MCI: Mild cognitive impairment; R: Right

Figure legends

Figure 1 Voxel-based group differences in FC. Differences between CU, AD-MCI and AD-dementia groups (*t*-tests) in neurotransmitter-enriched functional connectivity across different receptor pathways (significance cluster-forming threshold of *p* < 0.001 with family-wise error correction)

Figure 2 Voxel-based FC-cognition associations across groups. Associations (multiple regressions) between neurotransmitterenriched functional connectivity and episodic memory performance in dopaminergic and cholinergic receptor pathways across the whole sample (including CU, AD-MCI and AD-dementia; significance cluster-forming threshold of p < 0.001 with family-wise error correction). CS: Composite score, MCL: Mesocorticolimbic, NST: Nigrostriatal

Figure 3 Sensitivity analysis. This figure shows differences (*t*-tests; panels a and *c*) in neurotransmitter-enriched functional connectivity (FC) between $A\beta$ + patients (AD-MCI and AD-dementia) and $A\beta$ - CU older adults and associations (multiple regressions; panel b) between neurotransmitter-enriched functional connectivity and episodic memory (LM-DR) in all $A\beta$ + participants (including CU, AD-MCI and AD-dementia; significance cluster-forming threshold of *p* < 0.005 with family-wise error correction)





Figure 1 Voxel-based group differences in FC. Differences between CU, AD-MCI and AD-dementia groups (ttests) in neurotransmitter-enriched functional connectivity across different receptor pathways (significance cluster-forming threshold of p < 0.001 with family-wise error correction)

114x189mm (300 x 300 DPI)



Figure 2 Voxel-based FC-cognition associations across groups. Associations (multiple regressions) between neurotransmitter-enriched functional connectivity and episodic memory performance in dopaminergic and cholinergic receptor pathways across the whole sample (including CU, AD-MCI and AD-dementia; significance cluster-forming threshold of p < 0.001 with family-wise error correction). CS: Composite score, MCL: Mesocorticolimbic, NST: Nigrostriatal

134x169mm (300 x 300 DPI)





Figure 3 Sensitivity analysis. This figure shows differences (t-tests; panels a and c) in neurotransmitterenriched functional connectivity (FC) between A β + patients (AD-MCI and AD-dementia) and A β - CU older adults and associations (multiple regressions; panel b) between neurotransmitter-enriched functional connectivity and episodic memory (LM-DR) in all A β + participants (including CU, AD-MCI and AD-dementia; significance cluster-forming threshold of p < 0.005 with family-wise error correction)

112x94mm (300 x 300 DPI)

